ClinicalJanuary 2026
2026 Review: Nanobodies as Next-Generation Therapeutics for Autoimmune Diseases Including MS
A comprehensive review in International Immunopharmacology evaluates therapeutic nanobodies in autoimmune and inflammatory diseases (lupus, RA, MS, IBD, T1D). Preclinical data shows nanobodies effectively modulate key immune targets, and early clinical studies confirm favorable safety profiles.
JFInnova Perspective
This review positions nanobodies as the next therapeutic frontier in autoimmunity, validating JFInnova's bet on the VHH format. JFIN-0001 is the only AI-designed anti-CD74 VHH in this landscape.
References
1
Nanobodies for autoimmune and inflammatory diseases
International Immunopharmacology · 2026
nanobody autoimmune MS therapeutic VHH